Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma

European Urology

Volumn 70, Issue 6, 2016, Pages 1006-1015

  Grünwald, Viktor ^a   Lin, Xun ^b   Kalanovic, Daniel ^b   Simantov, Ronit ^c  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b PFIZER INC   (United States)

^c Pfizer Ltd   (United States)

Author keywords

Early tumour shrinkage; Overall survival; Predictive factor; Prognostic factor; Progression free survival; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; CALCIUM; HEMOGLOBIN; LACTATE DEHYDROGENASE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE; PYRROLE DERIVATIVE; RAPAMYCIN;

AGED; ARTICLE; CALCIUM BLOOD LEVEL; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; KIDNEY METASTASIS; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PATIENT HISTORY OF NEPHRECTOMY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SYSTEMIC THERAPY; ANALOGS AND DERIVATIVES; BONE TUMOR; DISEASE FREE SURVIVAL; KIDNEY TUMOR; LIVER TUMOR; LUNG TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REMISSION; RENAL CELL CARCINOMA; RETROSPECTIVE STUDY; SECONDARY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR VOLUME;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BONE NEOPLASMS; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; IMIDAZOLES; INDAZOLES; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PYRROLES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SIROLIMUS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84969857927     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.05.010     Document Type: Article

References (33)

1. [1] Shek, D., Tomlinson, B., Brown, M., Brunson, A., Pan, C.X., Lara, P.N. Jr., Epidemiologic trends in renal cell carcinoma in the cytokine and post-cytokine eras: a registry analysis of 28,252 patients. Clin Genitourin Cancer 10 (2012), 93–98.
2. [2] Therasse, P., Arbuck, S.G., Eisenhauer, E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000), 205–216.
3. [3] Adjei, A.A., Christian, M., Ivy, P., Novel designs and end points for phase II clinical trials. Clin Cancer Res 15 (2009), 1866–1872.
4. [4] Abel, E.J., Culp, S.H., Tannir, N.M., Tamboli, P., Matin, S.F., Wood, C.G., Early primary tumor size reduction is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol 60 (2011), 1273–1279.
5. [5] Krajewski, K.M., Guo, M., Van den Abbeele, A.D., et al. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma. Eur Urol 59 (2011), 856–862.
6. [6] Krajewski, K.M., Franchetti, Y., Nishino, M., et al. 10% Tumor diameter shrinkage on the first follow-up computed tomography predicts clinical outcome in patients with advanced renal cell carcinoma treated with angiogenesis inhibitors: a follow-up validation study. Oncologist 19 (2014), 507–514.
7. [7] Grunwald, V., McKay, R.R., Krajewski, K.M., et al. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol 67 (2015), 952–958.
8. [8] Seidel, C., Busch, J., Weikert, S., Steffens, S., Bokemeyer, C., Grunwald, V., Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC). Br J Cancer 109 (2013), 2998–3004.
9. [9] Motzer, R.J., Hutson, T.E., Olsen, M.R., et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 30 (2012), 1371–1377.
10. [10] Motzer, R.J., Rini, B.I., Bukowski, R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006), 2516–2524.
11. [11] Escudier, B., Roigas, J., Gillessen, S., et al. Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma. J Clin Oncol 27 (2009), 4068–4075.
12. [12] Motzer, R.J., Michaelson, M.D., Redman, B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006), 16–24.
13. [13] Barrios, C.H., Hernandez-Barajas, D., Brown, M.P., et al. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma. Cancer 118 (2012), 1252–1259.
14. [14] Motzer, R.J., Hutson, T.E., Tomczak, P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007), 115–124.
15. [15] Rini, B.I., Melichar, B., Ueda, T., et al. Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial. Lancet Oncol 14 (2013), 1233–1242.
16. [16] Rini, B.I., Escudier, B., Tomczak, P., et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378 (2011), 1931–1939.
17. [17] Hutson, T.E., Lesovoy, V., Al-Shukri, S., et al. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial. Lancet Oncol 14 (2013), 1287–1294.
18. [18] Qin, S., Bi, F., Jin, J., et al. Axitinib versus sorafenib as a second-line therapy in Asian patients with metastatic renal cell carcinoma: results from a randomized registrational study. Onco Targets Ther 8 (2015), 1363–1373.
19. [19] Hutson, T.E., Escudier, B., Esteban, E., et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol 32 (2014), 760–767.
20. [20] Hudes, G., Carducci, M., Tomczak, P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007), 2271–2281.
21. [21] Rini, B.I., Bellmunt, J., Clancy, J., et al. Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 32 (2014), 752–759.
22. [22] Heng, D.Y., Xie, W., Regan, M.M., et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostics model: a population-based study. Lancet Oncol 14 (2013), 141–148.
23. [23] WHO handbook for reporting results of cancer treatment. World Health Organization Offset Publication No. 48. Geneva, Switzerland: World Health Organization; 1979.
24. [24] Grünwald V, Litiere S, Young RJ, et al. Absence of progression, not extent of remission defines prognosis in soft tissue sarcoma–an analysis of the EORTC 62012 study [abstract 3401]. Presented at: European Cancer Congress; September 26, 2015; Vienna, Austria.
25. [25] Prasad, V., Kim, C., Burotto, M., Vandross, A., The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med 175 (2015), 1389–1398.
26. [26] Prentice, R.L., Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 8 (1989), 431–440.
27. [27] Krajewski, K.M., Nishino, M., Franchetti, Y., Ramaiya, N.H., Van den Abbeele, A.D., Choueiri, T.K., Intraobserver and interobserver variability in computed tomography size and attenuation measurements in patients with renal cell carcinoma receiving antiangiogenic therapy: implications for alternative response criteria. Cancer 120 (2014), 711–721.
28. [28] McDermott, D.F., Drake, C.G., Sznol, M., et al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J Clin Oncol 33 (2015), 2013–2020.
29. [29] Claret, L., Mercier, F., Houk, B.E., Milligan, P.A., Bruno, R., Modeling and simulations relating overall survival to tumor growth inhibition in renal cell carcinoma patients. Cancer Chemother Pharmacol 76 (2015), 567–573.
30. [30] Heinemann, V., Stintzing, S., Modest, D.P., Giessen-Jung, C., Michl, M., Mansmann, U.R., Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur J Cancer 51 (2015), 1927–1936.
31. [31] Tunariu, N., Kaye, S.B., Desouza, N.M., Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?. Br J Cancer 106 (2012), 619–628.
32. [32] Choi, H., Charnsangavej, C., Faria, S.C., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25 (2007), 1753–1759.
33. [33] Heng, D.Y., Xie, W., Regan, M.M., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 27 (2009), 5794–5799.